Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial

Cheol Chung, Hyun; Arkenau, Hendrik-Tobias; Lee, Jeeyun; Young Rha, Sun; Oh, Do-Youn; Wyrwicz, Lucjan; Kang, Yoon‐Koo; Lee, Keun‐Wook; R. Infante, Jeffrey; Sook Lee, Sung; Kemeny, Margaret; Keilholz, Ulrich; Melichar, Bohuslav; C. Mita, Alain; Plummer, Ruth; Smith, Denis; B. Gelb, Arnold; Xiong, Huiling; Hong, Janet; K. Chand, Vikram; Safran, Howard

doi:10.1186/s40425-019-0508-1

Public

Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial

Published in Journal for ImmunoTherapy of Cancer • Feb 4, 2019

Authors:

Hyun Cheol Chung

Hendrik-Tobias Arkenau

Jeeyun Lee

Abstract

BACKGROUND: We evaluated the antitumor activity and safety of avelumab, a human anti-PD-L1 IgG1 antibody, as first-line switch-maintenance (1 L-mn) or second-line (2 L) treatment in patients with advanced gastric/gastroesophageal cancer (GC/GEJC) previously treated with chemotherapy. METHODS: In a p...

Subject

Medicine

Internal medicine

Avelumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!